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A glomerular permeability factor produced by human T cell
hybridomas
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and MITSUHARU NARITA
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A glomerular permeability factor produced by human I cell hybrid-
omas. T cell hybndomas derived from the T cells of a patient with
minimal change nephrotic syndrome (MCNS) made a glomerular per-
meability factor (GPF). Sufficient quantities of GPF were available for
further analysis and characterization. We obtained four stable clones of
human T cell hybridomas which produced a glomerular permeability
factor. When this factor was injected intravenously into rats, significant
proteinurias were induced, and in normal human lymphocyte culture,
GPF enhanced Concanavalin-A (Con-A) induced lymphocyte blastoge-
nesis by greater than ten fold. GPF was cytotoxic to tumor cell lines of
epithelial origin, but only cytostatic to tumor cells of hematopoietic
origin. Electron microscopy studies, with polyethyleneimine (PEI)
staining, indicated that GPF induced the changes in the arrangement of
PEI particles and partial fusion of glomerular epithelial cells in the rats
given this factor intravenously. The molecular weight of GPF were
estimated to be between 60,000 and 160,000 daltons. The molecular
weight of the factor and its TNF like activity, we speculated that the
factor was a lymphokine, like lymphotoxins.
Minimal change nephrotic syndrome (MCNS) is a common
cause of nephrotic syndrome in children. However, the patho-
genesis of this disease is still unknown. The glomerular capil-
laries from patients with MCNS have an abnormal permeability
to serum proteins, mainly albumin. Histological studies do not
indicate any glomerular injury to explain the observed abnormal
permeability, except for foot processes fusion of epithelial cell
[1].
Another feature of MCNS is abnormality of the T cell
functions [2—131. Several reports of immediate recurrence of
nephrotic syndrome in patients with steroid resistant MCNS
after kidney transplantation suggest the presence of humoral
factor enhancing the glomerular permeability [14]. In addition,
it has been reported that lymphocyte cultures obtained from
MCNS patients can be stimulated with Con-A to produce a
GPF, which causes urinary protein excretion in rats [15]. Based
on these observations, it has been postulated that GPF is a
lymphokine produced by T cells, and that it mediates abnormal
permeability in patients with nephrotic syndrome.The biologi-
cal profile of GPF resembles that of the skin reactive factor,
which has been extensively studied in guinea pigs [3, 4, 14]. The
skin reactive factor is thought to be a lymphokine produced by
T cells, which induces a rapid increase in vascular permeability
at the intradermal site of injection, followed several hours later
by a local inflammatory response. However, there have been no
observations of an equivalent hunian lymphokine exhibiting
similar biological activity to the skin reactive factor.
In an animal model of MCNS, injection of puromycin ami-
nonucleoside, leads to massive proteinuria and minor glomeru-
lar lesion, except for the foot proces:ses fusion of the epithelium
of the glomerular basement membrane (GBM). These changes
are similar to those of MCNS. This drug is thought to be toxic
to the epithelium of GBM, rather than mesangial cells [16].
The present paper describes the production of a GPF by T
cell hybridomas derived from T lymphocytes obtained from
patients with MCNS. The biological profile of this GPF was
consistent with that described in the literature. In addition, we
have further characterized the GPF by physical and biological
means.
Methods
Production of human T cell hybridomas
Peripheral blood was collected in heparin from three normal
volunteers and four patients with MCNS (cases; T, K, N, S),
who were nephrotic but had received no corticosteroid or
immunosuppressive agents and no histological changes by light
microscopy. The blood sample was mixed with equal volume of
phosphate buffered saline (PBS), overlaid on top of Percoll (d =
1,080; Pharmacia LKB Biotechnology, Sweden) and centri-
fuged at 880 x g for 20 minutes. The lymphocyte fraction was
isolated from the gradient and the cells were washed twice with
RPMI-l640 medium (Gibco Laboratories, Grand Island, USA).
To obtain the T cell hybridomas, about 1 X 108 purified
lymphocytes were fused with 5 x l0 CCRF-HSB-2 cells with
polyethylene glycol 4000 [17]. After fusion, the cells were
suspended in hypoxanthine/aminopterin/thyrnidine (HAT) me-
dium containing 20% fetal calf serum (FCS) and added to
96-well plates at a density of 1 X 106 cells per well. Thymus
cells from Balb/c mice served as feeders. The fused cells were
allowed to select in HAT or hypoxanthine/thymidine (HT)
media at 37°C in 5% CO2. After stable selection, the hybrid-
omas were then adapted to grow in RPMI-1640 containing 20%
FCS.
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Fig. 1. Induction of urinary protein excretion
by the injection of the crude supernatant of T
cell hybridomas. Before limiting dilution, one
ml of the crude hybridoma supernatants from
three normal volunteers and four patients with
MCNS were injected intravenously into 3
female Wistar rats to confirm the presence of
GPF in the culture supernatants. The data
represent mean in the rats (N = 3) given
crude supernatants at the first day after the
injections. The levels of urine protein excretion
in rats given the supernatants from patients
with MCNS are significantly higher than those
in the rats given supernatants from normal
human volunteers (S, P < 0.02; K, P < 0.01;
N, P < 0.05; T, P < 0.1).
In vivo assay of GPF
Before limiting dilution, one ml of the crude supernatants
from T cell hybridomas were injected intravenously into three
female Wistar rats (200 g each) to confirm the presence of GPF
in the culture supernatants; also one ml of the samples, which
were after limiting dilution, were injected intravenously into
three rats. Twenty-four hour urines were collected in the
metabolic cages. Amounts of urinary proteins were determined
by the sulfosalicylic acid method. The crude supernatants of
hybridomas from normal human volunteers were used as con-
trols.
Interleukin 2 assay by the MTH mouse IL-2 dependent ce/l
line and other cytokine assays
The MTH mouse interleukin 2 (IL-2) dependent cell line was
used for this assay. Five thousand cells were added to each well
of a 96-well plate. The test samples (50 p1) were serially diluted
in RPMI-1640 and added to the cells. After the cultures were
incubated at 37°C for 28 hours, 0.2 .tCi of tritiated thymidine
(3H-TdR: specific activity: 2 Cilmmol) was added to each well.
The cells were then labeled at 37°C for four hours and the
radioactivity incorporated was determined by liquid scintilla-
tion spectroscopy. As positive controls, serial diluted recombi-
nant human IL-2 (rIL-2) was used. Medium only and GPF
negative supernatants of hybridoma were used as controls. The
percent uptake was expressed as follows: % uptake (cpm of
samples — cpm of medium control)/(cpm of positive control —
cpm of medium control). The human cytokine assays were
performed by the enzyme-linked immunosorbent assay
(ELISA) kits. TNF-alpha, IL-i-alpha, IL-i-beta, and IL-2 in
the culture supernatants were measured by the ELISA kits
(Otsuka Pharmaceutical Co., Japan) and human IL-4 and IL-6
were measured by the Intertest-4 and -6 kits (Genzyme Corpo-
ration, Massachusetts, USA). TNF-beta and IL-2 were
Time, days after injection
Fig. 2. Induction of urinary protein excretion by the injection of the
supernatant of T cell hybridomas after limiting dilutions. One ml of
samples from four clones (—0—, N3C-A1; —Li—, N3D-C1; —D—,
N3C-B1; ——, N3D-D2), which were after limiting dilutions, were
injected intravenously into 3 rats. The rats given the supernatants from
CCRF-HSB-2 cell culture were used as negative control (N = 5;
——0——). Urine proteins were significantly induced by the injection of
these supernatants. The data represent mean SE (N = 3). +P <0.1,
*p < 0.05, < 0.01, < 0.005.
detected by the immunoblotting method [18], using rabbit
anti-human TNF-beta and IL-2 antibodies (Hayashibara Bio-
chemical Laboratories Inc., Japan).
Con-A induced lymphocyte blastformation assay
Normal human peripheral lymphocytes were prepared by
Ficoll-Conrey (d = 1.077) gradient centrifugation. One hundred
thousand cells in 0.2 ml of RPMI-1640 containing 10% FCS are
added to each well of a 96-well plate. Then, 20 p1 of Con-A (1
mg/mI) were added to each well. After the cells were incubated
for 12, 24 or 48 hours in the presence of Con-A, serial diluted
test samples were added. Three days later, 3H-TdR was added
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Table 1. Effect of supernatants of T cell hybridomas on Con A-induced blast formation in normal lymphocytes
Supernatant
Sample
addition
timea
Enhancement ratio of blast formationb supernatant dilution
—
1/320 1/160 1/80 1/40 1/20 1/10
N3D-D2 12 hr
24 hr
48hr
1.07
0.97
1.38
0.93
1.31
1.98
1.00
1.44
4.47
1.45
2.20
13.4
2.90
4.35
12.0
2.17
5.00
12.2
N3D-C1 12 hr
24hr
48hr
1.10
1.10
1.15
1.15
1.15
1.94
1.56
1.10
5.15
2.18
1.33
8.44
3.96
2.88
6.26
5.76
3.91
6.67
N3D-Bl 12 hr
24hr
48hr
—
—
—
—
—
—
0.99
1.11
4.64
1.43
1.26
11.6
2.79
3.92
11.5
3.01
4.79
11.8
a After the cells were incubated for 12, 24 or 48 hours in the presence of Con-A, serial diluted supernatants of the clones, N3D-D2, N3D-C1 and
N3C-C1 were added. Three days later, 3H-TdR was added to the cell cultures. The uptake of 3H-TdR after 4 hours of incubation was determined.
Supernatant from CCRF-HSB-2 culture was used as the control.
b The enhancement ratio of blast formation is expressed as CPM in sample/CPM in control.
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Fig. 3. Measurement of IL-2 in the
supernatants of T cell hydbridomas. Positive
control was serial diluted human rIL-2;
negative control was supernatant from CCRF-
HSB-2 culture. GPF-positive supernatants
were: N3D-D2, N31)-Cl, N3C-Bl, and N3C-
Al. GPF negative supernatants (Nol-No20).
% Uptake = (CPM of samples — CPM of
negative control)/(CPM of positive control —
100 CPM of negative control). The values in GPF
positive and many negative samples were
below 62.5 U/mI.
3H-TdR for four hours. The uptake of the 3H-TdR was deter-
mined by liquid scintillation spectrosccpy.
To examine the effect of GPF on human tumor cells of
epithelial origin, the semi-quantitative cytotoxic test was per-
formed by the modified Takasugi and Klein's method 119]. The
cell lines examined include carcinoma cells from the stomach,
the gall bladder, the prostate gland, the kidney, and squamous
cell carcinoma from the penis. Ten thousand cells were added
to each well of the 96-well plate and incubated in RPMI medium
containing 10% FCS for three days. The supernatant medium
was removed and fresh medium was added to the cell culture.
To these cells, serial diluted test samples were added. After a 48
hours incubation, the cells were fixed and stained with Giemsa
stain. The morphology of the cells were evaluated semiquanti-
tatively using the following criteria: 1) cytotoxic effect: (—)=
U
Uptake, %
—20
to the cell cultures. The uptake of 3H-TdR after four hours of
incubation was determined by liquid scintillation spectroscopy.
Supernatants from CCRF-HSB-2 culture were used as controls.
The enhancement ratio of blastformation was expressed as
CPM in sample/CPM in control.
Antiproliferation and cytotoxicity assays
To examine the antiproliferative effects of GPF on tumor
cells of human haematopoietic origin, the ability of these cells
to take up 3H-TdR was determined after the incubation of these
cells in the presence of the factor. Raji, Molt 3 and K562 cells
were used for these studies. Three hundred target cells were
added to each well of the 96-well plate and the serial dilutions of
the test samples were added to each well. The cells were then
incubated for 20 hours after which the cells were labelled with
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Table 2. Effect of the supernatants of T CeII hybridomas on the cell unes from epithelia! origin
Supernates dilution
1/10 1/20 1/40 1/80 1/160 1/240
Supernates CS CP Cs CP Cs CP CS CP Cs CP Cs CP
Prostatic Carcinoma
Control —
N3D-D3 -
N3D-D2 -
N3D-Cl —
N3D-A1 +
N3C-B1 +
N3C-C1 +
Renal cell carcinoma
Control —
N3D-D3 -
N3D-D2 -
N3D-C1 +
N3D-A1 ++
N3C-B1 ++
N3C-C1 ++
Squamous cell carcinoma
Control —
N3D-D3 -
N3D-D2 ++
N3D-C1 ++
N3D-A1 ++
N3C-B1 ++
N3C-C1 ++
—
-
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The supernatants exhibited cytostatic and/or cytopathogenic effects in cell lines of adenocarcinomas, especially squamous cell carcinoma.
1) cytotoxlc effect: (—)= no cytotoxic effect; (±) = less than 20% cytotoxic effect; (+) = 20 to 50% cytotoxic effect; (+ +) greater than 50%
cytotoxic effect; and 2) cytopathic effect: (—) = no significant morphological change; (±) =unclear; (+) = necrosis indicated; (+ +) = massive
necrosis.
Table 3. Computer assisted morphometric analysis of glomerular
anionic site distribution after injection of GPF-positive and
negative supernatants
Group GPF positive GPF negative P
Anionic sites
/10,000 A/GBM
Diameter (A)
of PEI particles
20.25 ± 1.5
(N = 4)
161.19 ± 36.19
(N = 70)
19.5 ± 0.577
(N = 4)
174.84 ± 44.74
(N = 70)
0.391
0.056
Density
of PEI particles
Interspacing (A)
117.18 ± 10.1!
(N 174)
457.84 ± 163.78(N = 90)
122.86 ± 11.34
(N = 174)
557.82 ± 179.11
(N = 78)
0.001
0.006
Data are presented as mean ± SD.
N in anionic sites is the number of the portion (10,000 A) in GBM; N
in diameter, density and interspacing is the number of PEI particles
counted in lamina rara externa of GBM.
no cytotoxic effect; (+1—) less than 20% cytotoxic effect; (+)
= 20 to 50% cytotoxic effect; (+ +) greater than 50% cytotoxic
effect; and 2) cytopathic effect: (—) = no significant morpho-
logical change; (+1—) = unclear; (+) = necrosis indicated;
(+ +) = massive necrosis.
Molecular weight determination
To determine the molecular weights of the protein, the GPF
from the T cell hybridoma cultures was fractionated by sucrose
density gradient (5 to 35%; linear sucrose density gradient in
PBS, pH 7.2, total volume; 15 ml) ultracentrifugation. The
supernatants (0.5 ml) were overlaid on the top of gradient and
centrifuged at 100,000 g for 24 hours in a Beckman L-4 series
ultracentrifuge (Beckman Instruments Inc., Palo Alto, Califor-
nia, USA) in a SW 27.1 rotor. Fractions (0.5 ml each) were
collected from the bottom of the tubes. The ability of the
protein(s) in each fraction to induce proteinurIa in the rat was
determined by the injection of the fractionated supernatants
(one ml) into rats. The molecular weights of the protein in
fractions exhibiting the proteinuria induction activity were
estimated in a parallel gradient using bovine albumin and
immunoglobulins as the molecular markers.
Histological examination
Histological evaluations of the renal tissues from rats injected
with the GPF positive and negative supernatants were carried
out by light microscopy, immunofluoresensce microscopy and
electron microscopy by the intravenous injection of PEI (1,800
daltons) [20, 21], At one hour after the injection of PEI, animals
were killed. A computer-associated morphometric analysis
were performed (Table 3) [21]. For immunofluorescent micros-
copy, fluorescein-conjugated goat anti-human IgG, anti-human
IgA, anti-human 1gM, anti-rat IgG, C3 and albumin (Cappel,
Organon Teknika Co., Pennsylvania, USA) were used.
Statistical analysis
Quantitative results are expressed as mean ± SD and ana-
lyzed by one-way analysis of variance and Student's t-test for
paired and unpaired data.
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Fig. 4. Effect of the supernatant of cell growth in haematopoietic
origins. The proliferation of Raji and Molt 3 cells are inhibited in the
presence of the supernatants by hybridoma clones: N3D-C1, (—U—),
N3C-Al (—A---), N3D-D2 (—S----) and N3C-Bl (—s—). Supernatant
of K562 cell line (—0—) represent the controls.
Results
Production of human T cell hybridomas
Human T cell hybridomas were made from three normal
volunteers and four patients with MCNS. In all hybridoma cells
from normal volunteers, the GPF activity could not be detected
in the crude supernatants, which were before limiting dilution.
On the other hand, in the crude supernatants from patients, the
GPF could be detected in all four patients (Cases; N,T,K,S)
(Fig. 1). However during limiting dilutions, the GPF activities
were lost, except for one patient (Case N).
Production of GPF
To verify the production of GPF, culture media from nearly
50 hybridoma clones from a patient with MCNS (case N) were
examined for their ability to induce proteinuria in rats. Of all of
the hybridomas, media from four clones were shown to elevate
the levels of urinary proteins (higher than 15 mg/day) in rats
significantly, when compared to the normal level; below 2
mg/day (Fig. 2). This effect continued for two to three days after
injection of the media, and suggested that these four hybridoma
lines produce GPF.
Characterization of GPF
Effects of the supernatant on Con-A-induced lymphocyte
blastformation in normal human lymphocytes. The presump-
tive GPF produced by hybridoma clones N3D-D2, N3D-C1 and
N3C-B 1 enhanced the rate of Con-A-induced lymphocyte blast-
formation by 12.0-, 6.99- and 11.7-fold respectively, when
compared to the rate of induction in the presence of supernatant
from CCRF-HSB-2 cells, as indicated in Table 1. The enhance-
ment rate of induction was concentration dependent and this
effect was maximized when the presumptive GPF lymphokine
was added to the lymphocyte culture at late logarithmic prolif.
erative phase.
Antiprohferation and cytotoxicity assays. The GPF exhibited
an antiproliferative effect on huma:n tumor cells of hematopoi-
etic origin (Fig. 3). The proliferation of Raji, Molt 3 and K562
cells were inhibited in the presence of GPF produced by
hybridoma clones N3D-Cl, N3C-D2, N3D-D2 and N3C-B1. In
addition, the GPF exhibited cytostatic and/or cytopathogenic
effects in epithelial cell lines of adenocarcinomas, especially
squamous cell carcinoma (Table 2).
Interleukin 2 assay by the MTH mouse IL-2 dependent cell
line and other cytokine assays. To prove that the lymphokine
produced by these hybridoma clones was not IL-2, its ability to
induce the proliferation of IL-2 dependent cells was examined.
As indicated in Figure 4, these factors failed to support the
growth of the IL-2 dependent cells, confirming that the GPF
lymphokine produced by these hybridomas is not IL-2 and that
the GPF does not have IL-2-like activity, and IL-2 could not be
detected in the supernatants by the western blotting and ELISA
assay (at least below 0.31 ng/ml). IL-i-alpha and IL-i-beta
could not be detected in these supernatants: The concentration
of IL-l-alpha and IL-I-beta were below 7.8 pg/mI and 15.6
pg/mi, respectively. Those of IL-4 and IL-6 were below 0.19
ng/ml and 0.15 ng/ml, respectively.
The factor showed also TNF-like activity. Therefore, TNF-
alpha was assayed in these supernatants by ELISA. The
concentration of TNF-alpha was at least below 1.56 pg/mI.
TNF-beta could not detect in these supernatants by the immu-
noblotting method.
Detection of human immunoglobulins and anti-GBM anti-
bodies. No human immunoglobulins were detected in the su-
pernatants by ELISA and anti-GBM antibody could not be
detected by immunofluorecence microscopy.
Histological changes
Histopathological changes in the glomerular basement mem-
brane were examined in rats injected with GPF. Partial fusions
of epithelial foot processes were observed by electron micros-
copy. Computer-assisted morphometric analysis of glomerular
anionic sites in lamina rara externa revealed that though anionic
sites in lamina rata externa in both groups were almost same,
the site-site interspacing of PEI particles was significantly
decreased in the rat given GPF positive supernatant (457.84
163.78 A), compared to the rat given GPF negative supernatant
(557.82 179.11 A). The density and diameters of the PEI
A
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Fig. 7. Molecular weight of vascular permeability factor. The super-
natant of N3D-D2 was fractionated by sucrose density gradient (linear:
5 to 35%) ultracentrifugation. The ability of the protein(s) in each
fraction to induce proteinuria in the rat was determined. The molecular
weight of the protein in fractions exhibiting the proteinuria induction
activity was estimated in a parallel gradient using bovine albumin and
immunoglobulins as the molecular markers. Symbols are: (—s-—)
urinary protein after injection of supernatant; (--0--) markers.
Fig. 6. Immunofluorescence findings of the rats given the supernatants
of T cell hybridomas (N3D-D2). Albumin (a) and C3 (b) are observed
along the peripheral capillary walls in the rat given N3D-D2 superna-
tant.
particles in the rat given GPF positive supernatant were also
significantly decreased, compared to those in the control rat
(Table 3 and Fig. 5). These findings may suggest the changes in
the characteristics of the negative charge barrier may occur by
the injection of GFP. Immunofluorescence studies indicated
that rat immunoglobulins could not be detected. However, rat
albumin and C3 were detected along the peripheral capillary
walls (Fig. 6), suggesting an increased the glomerular perme-
ability. There was no human immunoglobulins in the glomeruli.
Molecular weight of GPF
The molecular weights of the GPF were estimated by sucrose
density gradient ultracentrifugation. The fractions of the gradi-
ent which induced proteinuria in rats as well as the deposition of
C3 and albumin along the peripheral capillary walls were
observed in the range of 60,000 to 160,000 daltons (Fig. 7).
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Fig. 5. Electron microscopic findings of rats
intravenously injected with the supernatant (N3D-
D2) of T cell hybridoma. (a) Partial fusions of
epithelial foot processes and changes in the
arrangement and sizes of PEI particles are observed
in the rat given N3D-D2 supernatant. (b) Regular
arrangement of PEI particles are observed in the rat
given GPF negative hybridoma supernatant (control).
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Discussion
MCNS is a unique disease, with several T cell abnormalities.
Factor(s) in the culture supernatants or sera from nephrotic
patients suppressed phytohemagulutinin (PHA)-induced blast
formation of the patients' lymphocytes. The massive protein-
uria may be due to the damage of negative charge barrier of the
GBM, which might be caused by lymphokine(s) [19, 201.
Therefore it is speculated that T cell lymphokines, which were
produced in patients with MCNS under the abnormal cellular
immunity, caused epithelial damages and massive proteinuria.
In this study we demonstrate that the factor caused signifi-
cant urinary protein excretion, which continued for two or three
days. Histological examination showed minor lesions with
partially fused foot process. The changes of PEI particles
(density, interspacing and diameter) in the GBM, which may be
caused by the injection of GFP suggest the changes in the
characteristics of negative charge barrier of the GBM [20—22].
Boulton-Jones et al demonstrated that the supernatants of
cultures of stimulated lymphocytes of patients with the ne-
phrotic syndrome containing autologous sera, when injured into
the renal arteries of rats caused patchy fusion of the foot
processes of epithelial cells and a reduction of charge on GBM
[23]. In the rats given fractions of the supernatants of T cell
hybridomas, linear staining of albumin and C3 were observed in
those fractions which caused urinary proteins. We speculated
that this linear patterns of albumin and C3 might be nonspecific
and due to the increase of permeability of the GBM, as is seen
in diabetic nephropathy [24]. Another mechanism of the gb-
merular injury may be in part due to complement mediated
mechanisms, such as membrane attack complex [25, 26].
There have been many reports that suppression of PHA-
induced blastformation occurs in lymphocytes from patients
with MCNS [9—13]. The factor showed tenfold more enhance-
ment of Con A-induced blast formation induced in normal
human lymphocytes. We have assayed IL-2 activity using the
MTH mouse IL-2-dependent cell. This factor could not enhance
the growth of this cell, but rather inhibited its growth and also
suppressed the proliferation of the hematopoietic cell lines.
There is discrepancy between lymphocyte function in pa-
tients with MCNS and the effects of our factor on normal and
abnormal lymphocytes in vitro. The reasons for this are not
clear. We speculate that lymphocyte function from patients
with MCNS may be suppressed, because lymphocytes have
already been activated by the factor, or suppressed blastogen-
esis may be caused by the addition of autologous sera, which
contains the factor. The factor may cause the T cell abnormal-
ities in MCNS.
It is of interest that the factor showed tumor necrosis
factor-like activity to tumors cells from epithelial cell origin.
The origin of the glomerular epithelium is not clear, but like
Bowman's capsule and tubular epithelial cells is thought to
originate from mesenchymal cells. The factor caused epithelial
cell necrosis, both in renal cell carcinoma and other carcinoma
cell lines. We could not clarify the exact sites of cell damage.
We speculate that the factor may be toxic to gbomerular
epithelial cells. Recently Thomson et al reported that lympho-
toxin (LT)-like substance, with MW 60,000—160,000 daltons,
could be detected in MCNS, as a suppressor of lymphocyte-
blastformation in the sera form patients with MCNS [271.
In our study, the molecular weight of the urinary protein
causing activity ranged between 60,000 to 160,000 daltons.
Though the molecular weight of the factor was roughly esti-
mated, it was larger than the other lymphokines, such as ILs
and interferons, but similar to those of LTs (molecular wt of
TNF-beta 60,000 to 70,000) [27—301. Of the molecular weight of
the factor and its TNF like activity, we speculated that the
factor was like LTs. However, we could not detect TNF-alpha,
TNF-beta, IL-l-alpha, IL-i-beta, 11-2, IL-4, or IL-6 by ELISA
and immunoblotting methods.
In conclusion, we have succeeded in producing a GPF from
four stable human T cell hybridomas and have partially char-
acterized this factor by physical and biological means. Further
studies are needed to clarify that this factor ha:s both the effects
of enhancement and suppression of cell growths, and to eluci-
date whether this factor is the etiological agent for MCNS.
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